Black Rock Inc. I Mab Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in I Mab stock. As of the latest transaction made, Black Rock Inc. holds 7,923 shares of IMAB stock, worth $11,884. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,923

Previous 100,065 92.08%

Holding current value

$11,884

Previous $190,000 92.63%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.54 - $2.37 $141,898 - $218,376	-92,142 Reduced 92.08%	7,923 $14,000
Q4 2023 Feb 13, 2024	SELL	$1.21 - $1.9 $754,090 - $1.18 Million	-623,215 Reduced 86.17%	100,065 $190,000
Q3 2023 Nov 13, 2023	SELL	$1.18 - $3.06 $1.58 Million - $4.09 Million	-1,335,361 Reduced 64.87%	723,280 $954,000
Q2 2023 Aug 11, 2023	BUY	$2.95 - $3.85 $330,370 - $431,161	111,990 Added 5.75%	2,058,641 $6.16 Million
Q1 2023 May 12, 2023	SELL	$3.08 - $7.39 $134,913 - $323,704	-43,803 Reduced 2.2%	1,946,651 $6.74 Million

Q4 2022 Feb 13, 2023	SELL	$3.22 - $4.86 $905,518 - $1.37 Million	-281,217 Reduced 12.38%	1,990,454 $8.32 Million
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $1.47 Million - $4.52 Million	-366,161 Reduced 13.88%	2,271,671 $9.11 Million
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $6.33 Million - $14.1 Million	-765,439 Reduced 22.49%	2,637,832 $29.8 Million
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $11.8 Million - $44 Million	938,531 Added 38.08%	3,403,271 $55.3 Million
Q4 2021 Feb 10, 2022	BUY	$45.28 - $74.5 $25.9 Million - $42.6 Million	572,142 Added 30.23%	2,464,740 $117 Million
Q3 2021 Nov 09, 2021	BUY	$57.18 - $84.43 $5.76 Million - $8.5 Million	100,726 Added 5.62%	1,892,598 $137 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $85.8 Million - $150 Million	1,791,872 New	1,791,872 $150 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account